Rapidly evolving market forces and technological advancements are prompting pharma companies to reimagine customer engagement, expand their roles within the health care ecosystem. Many companies are recruiting outside of life sciences for digital expertise Explore deloitte's collection of content surrounding biopharma industry trends with a focus on ai in biopharma.
OnlyFans Info - Semiocast
How might biopharma continue to innovate while building trust?
Inorganic growth activity in life sciences— have we reached the bottom
Discover industry insights and audit, tax, and consulting services that drive impact from deloitte’s global network of member firms. バイオ・創薬スタートアップは新規モダリティの創出の原動力であり、ひとたび新規モダリティが上市されると、それらは大きな市場を形成し、同時に業界構造についても大きな変化を引き起こす。多重特異性抗体や細胞治療の開発が進み、バイオCDMOの構造にも変化の兆候が見られる。 Deloitte us | audit, consulting, advisory, and tax services 2024年10月から11月にかけて実施された2025年度版グローバル自動車消費者調査では、次の4つの主要なトレンド取り上げる。 ほとんどの市場でバッテリー式電気自動車（BEV）への関心は依然として低調で、内燃機関（ICE）およびハイブリッド車（HEV）への関心が高まっている。 多くの市場において.
In 2024, many biopharma companies are looking for novel ways to marry the rich data sets of science with the latest genai technologies.15 alternatively, technology giants with advanced types of ai capabilities are looking to capitalize on the massive opportunities aforded by the life sciences and health care industry.16 by 2025, 36 percent of. More than 3/4 of biopharma companies agree that their organizations need new leaders to succeed in the digital age
